Neurocrine Biosciences [NBIX] — Trade Construction & Liquidity

Analysis date: 2026-07-29 · Spot $182.13 (Alpaca IEX, 2026-07-29 intraday) This document constructs no position and issues no verdict. It scores the Liquidity Criteria, states what can and cannot be filled, and specifies entry-timing and invalidation mechanics.

1. Liquidity Criteria — BINDING

1.1 Common stock — PASS

The ADV figure is a partial tape, not the consolidated number. IEX prints a low-single-digit share of US consolidated volume; the consolidated ADV for a $18.3bn Nasdaq Global Select constituent is materially higher. No consolidated figure is asserted, because this data source cannot produce one. On the partial tape alone a $10m position is roughly one day's IEX-printed volume.

1.2 Options — MARGINAL: exactly one contract is genuinely fillable

criteria.md: "Any proposed options structure requires the actual chain pulled first — open interest and quoted size for the specific strikes and expiry... A vehicle that cannot be filled is not a vehicle."

Full chain pulled from Alpaca (all expiries 2026-08-01 → 2028-01-31), with quotes, IV and Greeks from the snapshots endpoint.

Better than GMED in this same batch, but the depth is concentrated in a handful of strikes rather than spread across the chain. Where it actually sits:

One contract clears the bar: the December-2027 $170 call, with 2,053 contracts of open interest and a 7% bid-ask spread — the only strike in the entire NBIX complex where both depth and a tight quote exist together. It is roughly 17 months out, comfortably spanning the 12-month horizon, and modestly in the money ($170 strike vs $182.13 spot).

What this rules out: a call spread. A defined-risk structure needs a second liquid strike, and there is none — the next-deepest December-2027 strike is $220 with 27 contracts of open interest and a 21% spread. Selling that leg would give back a large fraction of the premium saved to the spread. The same problem defeats a collar (December-2027 puts were not separately depth-tested, but the call side already shows the chain is one-strike deep).

Conclusion. Common stock is the primary vehicle. If a book wants convexity, the 17 Dec 2027 $170 call is the only single-leg contract that can be filled at a rational price, and it must be sized against the fact that 2,053 contracts of open interest represents roughly $8.8m of notional premium at the mid — a book taking a meaningful share of it will move the quote.

Implied volatility across the quoted strikes runs 33–38%, against 252-day realised of 32.2%. Options are priced at a modest premium to realised — no obvious cheapness, no obvious richness.

2. Entry timing — the Momentum Criteria applied

MEASURED. Governs when, never whether.

Every momentum signal points the same way, which is the opposite of GMED in this batch. NBIX is at its 52-week high, above both moving averages, with three-month returns of +38.8%.

The timing tension is that RSI-14 at 52.3 is neutral while the stock sits at its high — the advance has been steady rather than parabolic, which is constructive, but there is no pullback to enter into. A book buying today pays the high and does so within days of a Q2 print (NBIX reported Q2 2025 on 30 July 2025).

That print carries three things that can move the stock hard in either direction: the first VYKAT XR consolidation, the first Soleno purchase accounting, and confirmation or refutation of INGREZZA's Q1 re-acceleration. Entering ahead of it is a decision to take event risk at the 52-week high. That is a sizing question, not a selection question, and this memo does not answer it.

3. Invalidation — what would falsify the analysis

4. Position mechanics, if a book chooses to own it

Specified, not recommended.

• Vehicle: common stock, primarily. Optional convexity via the 17 Dec 2027 $170 call only — see §1.2. No spread structure is proposable at this chain depth.
• Sizing input — inverse volatility. 252-day realised volatility is 32.2%, versus GMED's 45.7% in this same batch. Under the book's inverse-volatility convention NBIX sizes roughly 1.4x larger than GMED for the same risk contribution. That is the mechanical consequence of the two vol figures and it is the correct first-order answer, but it should be overridden downward for one reason stated explicitly: realised volatility does not price a patent-litigation binary. The Zydus case is a discrete, un-hedgeable, one-sided event that a 32% trailing vol does not contain. This is precisely the case criteria.md has in mind when it says inverse-vol sizing works "because a fat-left-tail name is almost always a high-volatility name" — NBIX is the exception to that generalisation, and a book relying on the mechanical output here would be under-protected.
• Correlation note for concentration limits: sub-sector tag Pharma. Named peer for spread purposes is ACADIA (ACAD); the direct competitive exposure is Teva's AUSTEDO in tardive dyskinesia, which NBIX named in its own release for the first time in 2025Q4. No overlap with the batch's medtech names except at the sector-beta level.
• Catalyst density: extreme and immediate. Q2 2026 results are expected within days, and they carry three distinct new disclosures at once.

5. Liquidity Criteria — result